Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.
Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
Harness Therapeutics' CEO talked to In Vivo about the company's strategy for expansion and partnering in the neurodegeneration space.
